Recently, 25% human albumin independently developed by Grand Shuyang, a subsidiary of Grand Life Sciences Group Co., Ltd., was officially approved for marketing by the National Medical Products Administration (NMPA). The marketing of this product fills the supply gap for high-concentration human albumin in the Chinese market and provides more efficient and precise treatment protocols for critically ill patients in clinical settings.

About 25% human albumin

Exceptional volume expansion and stable hemodynamics

With a colloid osmotic pressure 4–5 times that of common solutions, 25% human albumin can rapidly increase blood volume, maintain hemodynamic stability, and persist intravascularly (> 16 h), demonstrating superiority over crystalloids.

Potent dehydrating effect and alleviation of edema

With a colloid osmotic pressure 5 times that of normal plasma, it can effectively reduce interstitial fluid and is indicated for the adjuvant treatment of resistant edema, including brain edema, cirrhosis ascites, and nephrotic syndrome.

Rapid correction of hypoproteinemia

It can enhance serum albumin levels more efficiently, particularly in patients with hypoproteinemia resulting from liver cancer surgery or severe infections, thereby improving clinical prognosis.

Reduction of fluid resuscitation burden and optimization of critical care management

For patients requiring substantial fluid resuscitation (such as those with acute lung injury), compared with lower-concentration albumin or crystalloids, it can significantly reduce fluid resuscitation volume, prevent fluid overload, and enhance treatment safety.

The recently approved 25% human albumin of Grand Shuyang expands the human albumin product portfolio, providing physicians and patients with superior treatment options and promoting advancement in Chinese critical care standards.